Evidence map›Paper›PMID 35070374›Full record

ArticleJournal of thoracic disease2021

3'-daidzein sulfonate protects myocardial cells from hypoxic-ischemic injury via the

Xueliang Zeng, Junjian Yu, Taohui Zeng, Yuan Liu, Bei Li

Open access · diamondAbstract read
In one paragraph

Article in Journal of thoracic disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xueliang ZengDepartment of pharmacy, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Junjian YuCardiovascular and Thoracic Surgery Department 2, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Taohui ZengDepartment of pharmacy, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Yuan LiuDepartment of pharmacy, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Bei LiDepartment of pharmacy, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
First Affiliated Hospital of Gannan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyocardial infarction (MI) has a high mortality and disability rate and greatly affects human health. This study sought to explore the therapeutic effect and molecular mechanism of 3'-daidzein sulfonate (DSS) on MI.

methodsA rat MI model was established and low and high doses of DSS were administered to the rats. An

resultsThe results of Hematoxylin and eosin, TUNEL, and Masson staining showed that the myocardial tissue of the MI group was repaired by DSS. The serum levels of cardiac troponin I (

conclusionsIn conclusion, this study first identified the beneficial role of DSS in MI. DSS protected myocardial cells by activating the

Indexed as

3'-daidzein sulfonateapoptosisHO-1Myocardial infarction (MI)NRF-2

Identifiers

PMID35070374
PMCPMC8743394
OpenAlexW4200026878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.